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We selected bone-metastatic prostate cancer as the target form of recurrent prostate cancer and 
developed a suicide-gene therapy based on an adenovirus vector with an organ-specific osteocalcin 
promoter. Related clinical studies have already been conducted in the United States at the University 
of Virginia， where results so far have established the safety of this therapy. In the present paper， in
addition to presenting the results of these gene四therapystudies from the basic research to the clinical 
stage， we discuss the clinical studies begun by our group in August 2003. 
In the 21st century， therapeutic systems in use are undergoing major changes. Gene therapy is 
likely to become an important therapeutic option in recurrent prostate cancer. In terms oftheorγand 
technology however， this form oftreatment is stil at a very immature stage ofdevelopment. We look 
forward to evolution in this field to provide an established treatment for recurrent prostate cancer and 
are committed to actively continuing with the development of gene therapy through translational 
research. 
(Hinyokika Kiyo 51: 75-79， 2005) 




























































































































































































-Patients 1，2， 3 2.5X109pfu 




























































有効性評価は， 1) PSA効果判定基準による com-
plete response (CR)， partial response (PR)， stable 
disease (SD)， progressive disease (PD)の評価によ
り行う.
2) Ad-OC-TK注入病変部の治療効果判定基準に
よる completeresponse (CR)， partial response 




of Recombinant DNA Activities (ORDA : I日RAC)
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